Human neural stem cell resource seed bank and construction method thereof
Through strict cell screening and quality control, a seed bank of human neural stem cells resources was constructed, which solved the problem of standardized construction of human embryo-derived neural stem cells, achieved long-term preservation and expansion of high-purity and high-active cells, and promoted the neural stem cells Clinical application and research development.
Patent Information
- Application Number
- CN202411046138.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-22
AI Technical Summary
The existing technology lacks standardized construction technology for human embryonic neural stem cells, which has led to hindering its clinical application, and the problems of low purity, poor activity and insufficient source of neural stem cells have not been effectively solved.
Through strict cell screening, identification, preservation and quality control, a seed bank of human neural stem cell resources is built, including tissue collection, tissue processing, cell culture and quality detection, ensuring the high purity, high activity and safety of neural stem cells and establishing standardization neural stem cell seed bank.
Long-term preservation and large-scale expansion of neural stem cells has been achieved, the quality stability of cells has been improved, the development of neural stem cells and their transformation research has been promoted, and the problems of low purity, poor activity and insufficient source have been solved.
Smart Images

Figure CN118996637A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of seed cell bank construction, and specifically relates to a human neural stem cell resource seed bank and a construction method thereof. Background Art
[0002] The incidence of neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, etc.) is increasing year by year. There is currently no effective cure for these diseases, and neural stem cells, with their potential for self-renewal and multidirectional differentiation, provide new hope for the treatment of neurodegenerative diseases. Although neural stem cells have great application prospects, their sources are relatively limited. Human tissue is one of the important sources of neural stem cells, but due to technical limitations, their acquisition and utilization face many challenges.
[0003] Before neural stem cells are applied to the study of the mechanism of neurological diseases, drug screening and treatment methods, not only the problem of cell source must be solved, but also the problem of cell quality and safety. The construction of a standardized and normalized neural stem cell seed bank is a necessary prerequisite for neural stem cell and translational research. Due to the lack of construction technology for a specific type of stem cell bank derived from human embryos, the clinical application and development of neural stem cells derived from human embryos have been greatly hindered. Based on this, it is urgent to develop a set of neural stem cell bank construction technology methods suitable for clinical applications to cope with the current development of the neural stem cell field. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide a human neural stem cell resource seed bank and a construction method thereof. The construction method of the present invention obtains high-purity, high-quality neural stem cell seed cells to achieve long-term preservation and large-scale expansion of neural stem cells, thereby solving the problems of low purity, poor activity, and insufficient source.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The present invention provides a method for constructing a human neural stem cell resource seed bank, comprising the following steps:
[0007] The isolated central nervous tissue was cut into tissue blocks and digested in a centrifuge tube with tissue digestion solution for 15-20 minutes, then centrifuged and the supernatant was discarded. The cells were resuspended with DMEM / F12 medium, centrifuged and the supernatant was discarded to collect the cell precipitate.
[0008] The cell pellet is resuspended into a single cell suspension and cultured in a bottle for 10 to 14 days to collect neurospheres; the neurospheres are digested with a cell digestion solution, centrifuged, and then the cells are resuspended and centrifuged again to obtain P0 generation cells;
[0009] The P0 cells were subcultured according to the above process to harvest the P3 cells, which were then cryopreserved after quality testing.
[0010] Preferably, the temperature during tissue digestion is 30-40°C.
[0011] Preferably, according to 1.0×10 5 ~1.5×10 5 The inoculum concentration was 100 / mL and the culture was spread in bottles.
[0012] Preferably, liquid is added and / or replaced during the flask culture process.
[0013] Preferably, the cooling program during the freezing is to drop the temperature to -80°C at a cooling rate of 1 to 3°C / min.
[0014] Preferably, the quality inspection includes cell appearance, cell morphology, cell viability and quantity, cell phenotype inspection, human STR profile analysis, chromosome karyotype inspection, sterility inspection, mycoplasma inspection, bacterial endotoxin inspection, genetic disease inspection, and human virus inspection.
[0015] More preferably, the qualified standards for cell viability and cell number are that the cell viability is ≥ 80.0%, and the cell number in a unit cryopreservation container is ± 20% of the labeled amount.
[0016] More preferably, the qualified standard of the cell phenotype is that the ratio of SOX2-positive cells is not less than 90%; the ratio of NESTIN-positive cells is not less than 90%.
[0017] More preferably, the chromosome karyotype detection comprises the following steps: taking neurospheres cultured to a diameter of 50 μm to 100 μm, inoculating them into a culture bottle coated with matrix gel, and then performing chromosome karyotype analysis using G banding.
[0018] The present invention also provides a human neural stem cell resource seed bank obtained by the construction method.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The human neural stem cell resource seed bank involved in the present invention mainly includes sections such as tissue collection, tissue processing, cell culture, quality inspection and information management. The present invention establishes a neural stem cell resource seed bank derived from human embryonic tissue through strict cell screening, identification, preservation, quality control and information management, aiming to establish a standardized and standardized neural stem cell seed cell bank to ensure the quality stability of neural stem cells and promote the development of neural stem cells and their transformation research. The human neural stem cell resource seed bank of the present invention strictly follows the GMP standards, ensuring the safety and effectiveness of the neural stem cell preparation process and high-quality management during the storage process, so as to achieve long-term preservation and large-scale expansion of neural stem cells, thereby solving the problems of low purity, poor activity, and insufficient sources. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 A flowchart for constructing a human neural stem cell resource seed bank of the present invention;
[0022] Figure 2 This is the cell morphology in culture after thawing for 1 year after cryopreservation;
[0023] Figure 3 This is the cell morphology in culture after thawing for 2 years;
[0024] Figure 4 This is the cell morphology in culture after thawing for 3 years. DETAILED DESCRIPTION
[0025] The present invention provides a method for constructing a human neural stem cell resource seed bank, comprising the following steps: cutting the separated central nervous tissue into tissue blocks, adding tissue digestion solution to a centrifuge tube, digesting for 15min to 20min, centrifuging and discarding the supernatant, resuspending with DMEM / F12 culture medium, centrifuging and discarding the supernatant to collect the cell precipitate; resuspending the cell precipitate into a single cell suspension and culturing in a bottle for 10 to 14 days, and collecting neurospheres; digesting the neurospheres with cell digestion solution, resuspending the cells after centrifugation, and then centrifuging to obtain P0 generation cells; subculturing the P0 generation cells according to the above process to harvest the P3 generation cells, and freezing after quality inspection. In the present invention, the source of the DMEM / F12 culture medium is not particularly limited, and conventional commercial products can be used. In the specific implementation of the present invention, the DMEM / F12 culture medium is purchased from Thermo Fisher Scientific (gibco).
[0026] In the present invention, the central nervous tissue is peeled off and cut into tissue blocks of 1mm×1mm×1mm in size, and then digested, enriched, inoculated, cultured, and passaged to the P3 generation. After passing the quality inspection, the blocks are frozen and stored as neural stem cell seed bank resources.
[0027] In the present invention, the neural stem cells are mainly derived from human embryonic tissue samples; or neural stem cells that can be differentiated from induced pluripotent stem cells (iPS cells). In the present invention, the separation of central nervous tissue preferably includes the following steps: placing the intact tissue in a culture dish, repeatedly rinsing with physiological saline until there is no obvious blood streak; under a dissecting microscope, using ultra-fine ophthalmic forceps and ophthalmic scissors, peeling off the central nervous tissue, using elbow surgical forceps to bluntly separate the central nervous tissue, and using fine surgical forceps to remove the vascular membrane around the tissue; dividing the separated central nervous tissue into tissue blocks of about 1mm×1mm×1mm in size according to the location.
[0028] In the present invention, the tissue block is digested after it is obtained. In the present invention, the tissue digestion preferably includes the following steps: placing the divided tissue block in a centrifuge tube, adding an appropriate amount of digestive fluid and shaking it gently, placing it in a thermostat at 30-40°C for digestion for 15-20 minutes, and gently shaking it every 5 minutes; after completing the digestion, centrifuge (500g, 2-5 minutes) to collect the cell precipitate, and add DMEM / F12 culture medium to resuspend the precipitate, repeat the above operation 2-3 times; aspirate the supernatant, add neural stem cell complete culture medium, gently blow and resuspend into a single cell suspension. In the present invention, the temperature during tissue digestion is more preferably 35°C. In the present invention, the source of the tissue digestion fluid is not particularly limited, and conventional commercially available products can be used. In a specific embodiment of the present invention, the tissue digestion solution is purchased from Thermo Fisher Scientific (gibco); the components of the tissue digestion solution preferably include L-cysteine 0.2-0.5 mg / mL, papain 8-15 U / mL, DNase 0.01-0.1 mg / mL, DMEM / F12 culture medium; more preferably include L-cysteine 0.43 mg / mL, papain 10 U / mL, DNase 0.06 mg / mL, DMEM / F12 culture medium. In a specific implementation of the present invention, the method for preparing the tissue digestion solution is: dissolving L-cysteine, papain, and DNase in DMEM / F12 culture medium. In the present invention, the source of the complete culture medium for neural stem cells is not particularly limited, and conventional commercial products can be used. In a specific embodiment of the present invention, the neural stem cell complete culture medium formula is preferably based on DMEM / F12 as the basic culture medium, supplemented with B27 serum-free additive, GlutaMAX, MEM sodium pyruvate, N2 preparation, acetylcysteine, basic fibroblast growth factor bFGF, epidermal growth factor EGF and leukemia inhibitory factor LIF.In a specific embodiment of the present invention, the neural stem cell complete medium is preferably calculated based on the total volume of DMEM / F12 medium, the volume fraction of the B27 serum-free additive is 1-3%, the volume fraction of the GlutaMAX is 1-3%, the volume fraction of the MEM sodium pyruvate is 1-3%, the volume fraction of the N2 preparation is 0.5-2%, the added amount of acetylcysteine is 1-2 mg / mL, the added amount of the basic fibroblast growth factor bFGF is 10-30 ng / mL, the added amount of the epidermal growth factor EGF is 10-30 ng / mL, and the added amount of the leukemia inhibitory factor LIF is 10-20 ng / mL. The added amount is 5 to 15 ng / mL; more preferably, the total volume of the DMEM / F12 medium is used as the complete culture medium for neural stem cells, and the volume fraction of the B27 serum-free additive is 2%, the volume fraction of the GlutaMAX is 2%, the volume fraction of the MEM sodium pyruvate is 2%, the volume fraction of the N2 preparation is 1%, the added amount of acetylcysteine is 1.63 mg / mL, the added amount of the basic fibroblast growth factor bFGF is 20 ng / mL, the added amount of the epidermal growth factor EGF is 20 ng / mL, and the added amount of the leukemia inhibitory factor LIF is 10 ng / mL.
[0029] In the present invention, the tissue block is digested to obtain P0 cells. In the present invention, the culture method of P0 cells preferably includes the following steps: 5 ~1.5×10 5 The cells were inoculated into the ultra-low adsorption culture container and gently shaken to evenly distribute the cells in the complete culture medium. The inoculated cells were placed in a 35°C, 5% CO 2 The cells are cultured in a carbon dioxide incubator at a concentration of 10 to 14 days, and the cells should be suspended and grow in the form of neurospheres. In the present invention, as an practicable method, the harvesting time is determined according to the size of the neurospheres, and the diameter of the neurospheres generally does not exceed 400 μm.
[0030] In the present invention, during the P0 cell culture process, liquid addition and / or liquid replacement are performed. In the present invention, the liquid addition is preferably performed 2 to 3 days and 4 to 5 days after inoculation culture. In the present invention, the liquid replacement is preferably performed 7 to 8 days and 10 to 12 days after inoculation culture.
[0031] In the present invention, the cells are digested after the cell culture is completed. In the present invention, the cell digestion and counting include the following steps: after collecting the neurospheres, centrifuge (300g, 1 minute) to collect the cell precipitate and add an appropriate amount of cell digestion solution, place it in a thermostat at 35°C for digestion for 12min to 15min, and shake it gently every 3 minutes; after the digestion is completed, centrifuge (500g, 3 minutes) to collect the cell precipitate, add an appropriate amount of DMEM / F12 culture medium to resuspend the cells, and repeat the above operation twice; after washing, the cell precipitate is resuspended with an appropriate amount of neural stem cell complete culture medium, counted, and the harvested cells are P0 generation cells. In the present invention, the number of live cells in the P0 generation should not be less than the number of cells inoculated. In the present invention, the source of the cell digestion solution is not particularly limited, and conventional commercially available products can be used. In a specific embodiment of the present invention, the cell digestion solution is from Thermo Fisher Scientific (gibco).
[0032] In the present invention, the P0 generation cells are subcultured after being obtained, and the quality of the cells is tested at the P3 generation. In the present invention, the P1 to P3 generation subcultures refer to the process of obtaining the P0 generation cells.
[0033] In the present invention, quality inspection is performed on P3 generation cells; the quality inspection preferably includes cell appearance, cell morphology, cell viability and quantity, cell phenotype detection, human STR profile analysis, chromosome karyotype detection, sterility inspection, mycoplasma inspection, bacterial endotoxin inspection, genetic disease inspection, and human virus detection.
[0034] In the present invention, the cell morphology detection is: placing the cell culture container under a microscope, using the microscope to observe the state of cells at different stages or generations, and taking pictures. The qualified standard of cell morphology detection is: single cell state, uniform cell size, and complete cell morphology.
[0035] In the present invention, the cell appearance test is preferably: taking the cryopreservation tubes in which the cells are packaged and to be frozen, and visually inspecting the cryopreservation tubes and labels. The qualified standard for the cell appearance test is: the cryopreservation container is intact, without cracks, the label is intact, and the information is complete and identifiable.
[0036] In the present invention, the cell viability and cell number detection is preferably: diluting the cell suspension with AO / PI fluorescent dye solution at a ratio of 1:1, using a fluorescent cell counter for detection, and recording the cell viability and cell number detection results. The cell viability and cell number detection qualification standard is: cell viability ≥ 80.0%, and the number of cells in the unit cryopreservation container is the labeled amount ± 20%.
[0037] In the present invention, the cell phenotype detection is preferably: about 2.5×10 6Cells were added with 1 mL of Fixation and Permeabilization Solution and mixed. The membrane was fixed and permeated for 10 min at 4 °C. After washing and resuspending the cells with 1× Perm / Wash Buffer, they were transferred to three 1.5 mL EP tubes, with 50 μL in each tube. The blank control group, isotype control group, and experimental group were set up, and the corresponding dye reagents were added respectively. The cells were vortexed for 30 s and incubated at room temperature in the dark for 30 min. The cells were resuspended with 300 μL of 1× Perm / Wash Buffer, transferred to flow tubes, and cell phenotypes were detected by flow cytometry. The qualified standards for cell phenotype detection were: the ratio of SOX2 positive cells was not less than 90%; the ratio of NESTIN positive cells was not less than 90%.
[0038] In the present invention, the human STR profile analysis is preferably performed by extracting DNA from an appropriate amount of cells, amplifying 20 STR loci and Amelogenin sex identification loci using MicroreaderTM21 ID System, detecting PCR products using ABI3730xl genetic analyzer, analyzing the test results using GeneMapperID-X software (Applied Biosystems), and comparing with ATCC, DSMZ and ExPAS databases. The qualified standard for human STR profile analysis is: single cell source, no cross contamination.
[0039] In the present invention, the chromosome karyotype detection is preferably: taking neurospheres cultured to a diameter of about 50 μm to 100 μm, inoculating them to After culturing in Matrix GFR, LDEV-Free matrix gel-coated culture bottles, chromosome karyotype analysis was performed using G banding. The qualified criteria for chromosome karyotype detection are: 46 chromosomes, XX / XY; no chromosome deletion, ectopic, inversion and other structural aberrations.
[0040] In the present invention, the sterility test is preferably performed by referring to the "1101 Sterility Test Method" of the third general rule of the "Chinese Pharmacopoeia" (2020 edition), taking an appropriate amount of cell washing supernatant from tissue separation or centrifugation supernatant of cells to be frozen (500g, centrifuged for 3 minutes) of the P3 generation aliquots, and performing a sterility test by membrane filtration. The qualified standard for the sterility test is negative.
[0041] In the present invention, the mycoplasma test is preferably performed by taking an appropriate amount of cell washing supernatant from tissue separation or centrifugation supernatant of cells to be frozen (500g, centrifuged for 3 minutes) from the P3 generation aliquots, and performing mycoplasma test using nucleic acid method (PCR). The qualified standard for mycoplasma test is negative.
[0042] In the present invention, the bacterial endotoxin test is preferably: refer to the "1143 Bacterial Endotoxin Test Method" of the three general rules of the "Chinese Pharmacopoeia" (2020 edition), take an appropriate amount of tissue-separated cell washing supernatant or P3 generation subpackaged cell centrifugation supernatant to be frozen (500g, centrifuged for 3 minutes), and use Limulus amebocyte lysate (gel method) for bacterial endotoxin test. The qualified standard for bacterial endotoxin test is <0.5EU / mL.
[0043] In the present invention, the genetic disease test is preferably detected by OmniSeek whole exome detection method, taking an appropriate amount of cells to extract DNA, constructing a library, using hybrid capture reagent to complete target area capture, and using IlluminaNovaSeq / MG DNBSEQ-T7 to complete high-throughput sequencing. Through bioinformatics analysis, combined with current domestic and foreign industry guidelines and medical cognition, (possible) pathogenic variants in the sample genome are screened. The qualified standard for genetic disease examination is: no dominant genetic pathogenic gene mutation, no homozygous recessive genetic pathogenic gene mutation.
[0044] In the present invention, the human-origin virus detection is preferably: after centrifugation of the cell suspension, the supernatant is taken and checked by nucleic acid method (PCR method) or ELISA method detection kit. The qualified standard for human-origin virus detection is that HAV, HBV, HCV, HIV-1 / 2, HCMV, EBV, HTLV-1 / 2, HHV-6 / 7 / 8, HPV, TP, human parvovirus B19, human polyomavirus, etc. are all negative.
[0045] In the present invention, cells that have passed the quality inspection are cryopreserved. In the present invention, the cryopreservation procedure is preferably: cooling down to -80°C at a rate of 1-3°C / min; more preferably: cooling down to -80°C at a rate of 2°C / min.
[0046] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0047] Example 1
[0048] A method for constructing a human neural stem cell resource seed bank comprises the following steps: taking intact tissue and repeatedly rinsing it with physiological saline until there is no obvious blood streak, peeling off the brain tissue with ultrafine ophthalmic forceps and ophthalmic scissors under a dissecting microscope, removing the vascular membrane around the tissue with fine surgical forceps, separating the tissues of each brain region, and chopping them into tissue blocks of about 1mm×1mm×1mm in size as much as possible, collecting the tissue blocks in a centrifuge tube and adding an appropriate amount of digestion solution, digesting at 35°C for 15min, shaking gently every 5min, centrifuging at 500g for 3min, discarding the supernatant, resuspending with DMEM / F12 medium, centrifuging at 500g for 3min, and discarding the supernatant, repeating once. The collected cell pellet is gently blown and resuspended into a single cell suspension, and the suspension is adjusted to 1.0-1.5×10 5 The inoculum concentration was 0.1 / mL and the bottles were incubated at 35°C and 5% CO 2 The cells were cultured in a carbon dioxide incubator at a concentration of 1% for 14 days; the neurospheres were collected and digested for 15 minutes, gently shaken every 3 minutes, centrifuged at 500g for 3 minutes, and after the centrifugation, an appropriate amount of DMEM / F12 medium was added to resuspend the cells, and then centrifuged at 500g for 3 minutes and repeated once. The collected cells were recorded as P0 generation. The P0 generation cells were passed to P3 generation according to the above preparation process, and relevant quality tests were performed. After passing the test, they were frozen. Among them, the cooling program during freezing was to drop to -80°C at a cooling rate of 2°C / min.
[0049] Example 2
[0050] The difference from Example 1 is that the time for tissue digestion is 20 min, and the other steps remain unchanged.
[0051] Example 3
[0052] The difference from Example 1 is that the cell culture time is 10 days, and the other steps remain unchanged.
[0053] Comparative Example 1
[0054] The difference from Example 1 is that the time for tissue digestion is 10 min, and the other steps remain unchanged.
[0055] Comparative Example 2
[0056] The difference from Example 1 is that the time for tissue digestion is 25 min, and the other steps remain unchanged.
[0057] Comparative Example 3
[0058] The difference from Example 1 is that the cell culture time is 6 days, and the other steps remain unchanged.
[0059] Comparative Example 4
[0060] The difference from Example 1 is that the cell culture time is 18 days, and the other steps remain unchanged.
[0061] Comparative Example 5
[0062] The difference from Example 1 is that the cooling program during freezing is 4°C for 30 min, -20°C for 1 h, and -80°C overnight, and the other steps remain unchanged.
[0063] Comparative Example 6
[0064] The difference from Example 1 is that the cooling program during freezing is -40°C for 1 hour and -80°C overnight, and the other steps remain unchanged.
[0065] Comparative Example 7
[0066] The difference from Example 1 is that the cooling program during freezing is -80°C overnight, and the other steps remain unchanged.
[0067] (1) Tissue digestion time comparison verification test
[0068] The same batch of tissue samples were divided into 4 groups, digestion solution was added, and digestion was performed for 10min, 15min, 20min, and 25min respectively, and the digestion effect was observed.
[0069] Table 1 Effects of different tissue digestion times on cells
[0070]
[0071]
[0072] It can be seen from Table 1 that the cells obtained when the tissue digestion time was 15 to 20 min were easy to blow away and had a complete morphology.
[0073] (2) Cell culture time comparison verification test
[0074] The same batch of cells were divided into 4 groups and cultured for 6 days, 10 days, 14 days and 18 days respectively. The cell spheroid state was observed and the cells were collected.
[0075] Table 2 Effects of different cell culture time on cell spheres
[0076] Group Cultivation time Culture results Group 1 6 days The cell sphere is too small, the number of cell proliferation is small, and the cell yield is low Group 2 10 days Moderate cell spheroids, moderate cell proliferation numbers, moderate cell yields Group 3 14 days Moderate cell spheroids, moderate cell proliferation numbers, moderate cell yields Group 4 18 days The cell sphere is too large, there are many dead cells, and the cell yield is moderate
[0077] According to the results of the cell culture time comparison verification test in Table 2, the cell yield was low after 6 days of culture and could not meet the requirements for cell expansion; the cell sphere size was moderate after 10 and 14 days of culture, and the cell yield met the expansion requirements; after 14 days of culture, the cell sphere was too large, there were many dead cells, and the cell yield was not significantly improved compared with 14 days of culture.
[0078] (3) Comparison of different cryopreservation procedures
[0079] The same batch of cells was cooled using the same batch of serum-free cryopreservation solution with different cooling programs, and then stored in vapor phase liquid nitrogen to compare the cryopreservation effects.
[0080] Table 3 Effects of different cooling programs on cell viability and cell number
[0081]
[0082] The results of the comparative verification test of cells frozen with serum-free cryopreservation solution using different cryopreservation procedures are shown in Table 3. After the cells were frozen with the cryopreservation procedures of the four groups, the viability and number of revived cells were the highest when the temperature was lowered to -80°C at a cooling rate of 2°C / min.
[0083] Test Example 1
[0084] Material Type and Source
[0085] The human neural stem cell donors in this trial were collected from Shanghai Oriental Hospital (Ethics Review Approval No.:
[2022] Yanlinshen No. (072)). The donors were discarded aborted fetuses. The donors (pregnant women) were required to be healthy, 8-16 weeks pregnant, free of genetic diseases / family diseases, and the results of relevant infectious disease examinations met the requirements.
[0086] Preparation of neural stem cells (hNSCs)
[0087] According to the medical standards for donor screening, the intact tissue was taken and repeatedly rinsed with physiological saline until there was no obvious blood streak. Under the dissecting microscope, ultrafine ophthalmic forceps and ophthalmic scissors were used to peel off the brain tissue, and the vascular membrane around the tissue was removed with fine surgical forceps. The tissues of each brain region were separated and cut into tissue blocks of about 1mm×1mm×1mm in size as much as possible. The tissue blocks were collected in a centrifuge tube and an appropriate amount of digestion solution was added. Digestion was performed at 35℃ for 20min, and the tube was gently shaken every 5min. The supernatant was discarded after centrifugation at 500g for 3min, and the supernatant was discarded. The tube was resuspended in DMEM / F12 medium, and the supernatant was discarded after centrifugation at 500g for 3min. The cell pellet was gently resuspended into a single cell suspension according to 1.0-1.5×10 5 The inoculum concentration was 0.1 / mL and the bottles were incubated at 35°C and 5% CO 2 The cells were cultured in a carbon dioxide incubator at 40 °C for 14 days.
[0088] During the culture process, the operations of adding and replacing the liquid are performed: the liquid addition operation is performed 2 to 3 days and 4 to 5 days after inoculation and culture, and the liquid replacement operation is performed 7 to 8 days and 10 to 12 days after inoculation and culture.
[0089] After the culture is completed, the neurospheres are collected and digested for 12-15 minutes, gently shaken every 3 minutes, and centrifuged at 500g for 3 minutes. After the centrifugation, an appropriate amount of DMEM / F12 medium is added to resuspend the cells, and then centrifuged at 500g for 3 minutes and repeated once. The collected cells are recorded as P0 generation. P0 generation cells are passed to P3 generation according to the above preparation process, and relevant quality tests are performed. After passing the quality test, they are frozen.
[0090] Quality testing of neural stem cells (hNSCs)
[0091] Cell morphology: Place the cell culture container under a microscope, observe the status of cells at different stages or generations, and take pictures.
[0092] Appearance: Take the cryopreservation tubes that have been packaged with cells for cryopreservation and visually inspect the cryopreservation tubes and labels.
[0093] Cell viability and cell number: Dilute the cell suspension with AO / PI fluorescent dye in a 1:1 ratio, and use a fluorescent cell counter to detect the cell viability and cell number test results.
[0094] Cell phenotype detection: about 2.5×10 6 1 mL of Fixation and Permeabilization Solution was added to each cell, and the mixture was mixed. The membrane was fixed and permeabilized for 10 min at 4°C. After washing and resuspending the cells with 1×Perm / Wash Buffer, the cells were transferred to three 1.5 mL EP tubes, 50 μL per tube, and the corresponding reagents were added according to Table 4. The cells were vortexed for 30 s and incubated at room temperature in the dark for 30 min. The cells were resuspended with 300 μL of 1×Perm / Wash Buffer, respectively, and transferred to flow tubes for cell phenotype detection using flow cytometry.
[0095] Table 4 Cell phenotype detection reagents
[0096]
[0097] The blank control group in Table 4: only the target cell suspension (neural stem cells) is added, and no fluorescein-coupled antibody is marked, and the detection is performed under the corresponding channel. Whether the detection result is non-specific fluorescence, the positive-negative dividing line is marked according to its non-specific fluorescence signal value; the isotype control group: when the target cell suspension is added, fluorescein-coupled non-specific antibodies are added respectively (the antibody is the same type of antibody that specifically binds to the target antigen molecule of the cell detection, and does not specifically bind to the target antigen molecule), and the detection is performed under the corresponding channel. The fluorescence signal obtained by the detection is not the specific fluorescence signal generated by fluorescein, but represents the non-specific fluorescence of the cell itself, which is used to exclude the influence of fluorescein; the experimental group: when the target cell suspension is added, fluorescence-coupled specific antibodies are added respectively, and the detection is performed under the corresponding channel. The obtained fluorescence signals are analyzed, and the cells with fluorescence signal values above the positive-negative dividing line are positive cells.
[0098] Human STR profile analysis: Take an appropriate amount of cells to extract DNA, use MicroreaderTM21 ID System to amplify 20 STR loci and Amelogenin gender identification loci, use ABI 3730xl genetic analyzer to detect PCR products, use GeneMapperID-X software (Applied Biosystems) to analyze the test results, and compare them with ATCC, DSMZ and ExPAS databases.
[0099] Chromosome karyotype detection: Take neurospheres cultured to a diameter of about 50 μm to 100 μm and inoculate them to After culturing in Matrix GFR and LDEV-Free matrix gel-coated culture flasks, chromosome karyotype analysis was performed using G banding.
[0100] Sterility test: Refer to the sterility test method in 1101 of Part III of the "Chinese Pharmacopoeia" (2020 edition), take an appropriate amount of cell washing supernatant from tissue separation or centrifugation supernatant of P3 generation cells to be frozen (500g, centrifugation for 3 minutes), and perform sterility test by membrane filtration.
[0101] Mycoplasma test: Take an appropriate amount of cell washing supernatant from tissue separation or centrifugation supernatant of P3 generation cells to be frozen (500g, centrifugation for 3 minutes), and use nucleic acid method (PCR) to perform mycoplasma test.
[0102] Bacterial endotoxin test: Refer to the bacterial endotoxin test method in General Chapter 1143 of Part III of the "Chinese Pharmacopoeia" (2020 edition), take an appropriate amount of cell washing supernatant from tissue separation or centrifugation supernatant of P3 generation cells to be frozen (500g, centrifugation for 3 minutes), and use horseshoe crab reagent (gel method) for bacterial endotoxin test.
[0103] Genetic disease testing: Genetic disease testing uses the OmniSeek whole exome detection method to detect, take an appropriate amount of cells to extract DNA, construct a library, use hybrid capture reagents to complete the capture of the target area, and use IlluminaNovaSeq / MGDNBSEQ-T7 to complete high-throughput sequencing. Through bioinformatics analysis, combined with current domestic and international industry guidelines and medical cognition, (possible) pathogenic variants in the sample genome are screened.
[0104] Human virus detection: After centrifugation of the cell suspension, the supernatant was taken and checked using a nucleic acid method (PCR method) or ELISA test kit.
[0105] After three batches of human neural stem cell seed cells (P3) were cryopreserved, they were revived after 1, 2, and 3 years of cryopreservation, and the cell viability and number were counted and the cell morphology during the cell culture process was observed. The results are shown in Tables 5 and Figure 2 to Figure 4 .
[0106] Table 5 The ratio of viability and number of cells revived after 1 / 2 / 3 years of cryopreservation to cells before cryopreservation
[0107]
[0108] according to Figure 2 to Figure 4 As can be seen from Table 5, the neural stem cells in the seed cell bank constructed by the present invention still maintain a good growth state after being frozen for 3 years, growing in a suspended neurosphere shape. The cells still have a high cell viability and cell number after being frozen for 1, 2, and 3 years.
[0109] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for constructing a human neural stem cell resource seed bank, characterized in that: The steps include: The isolated central nervous system tissue was cut into tissue blocks and digested in a centrifuge tube with tissue digestion solution for 15 to 20 minutes, then centrifuged and the supernatant was discarded. The cells were resuspended with DMEM / F12 medium, centrifuged and the supernatant was discarded to collect the cell precipitate. The cell pellet is resuspended into a single cell suspension and cultured in a bottle for 10 to 14 days to collect neurospheres; the neurospheres are digested with a cell digestion solution, centrifuged, and then the cells are resuspended and centrifuged again to obtain P0 generation cells; The P0 cells were subcultured according to the above process to harvest the P3 cells, which were then cryopreserved after quality testing.
2. The construction method according to claim 1, characterized in that: The temperature during the tissue digestion is 30-40°C.
3. The construction method according to claim 1, characterized in that: According to 1.0×10 5 ~1.5×10 5 The cells were inoculated at a concentration of 100 / mL and cultured in flasks.
4. The construction method according to claim 1, characterized in that: During the flask culture process, liquid is added and / or replaced.
5. The construction method according to claim 1, characterized in that: The cooling program during the freezing is: cooling to -80°C at a cooling rate of 1-3°C / min.
6. The construction method according to claim 1, characterized in that: The quality inspection includes cell appearance, cell morphology, cell viability and quantity, cell phenotype inspection, human STR profile analysis, chromosome karyotype inspection, sterility inspection, mycoplasma inspection, bacterial endotoxin inspection, genetic disease inspection, and human virus inspection.
7. The construction method according to claim 6, characterized in that: The qualified standards for cell viability and cell quantity are that the cell viability is ≥ 80.0%, and the cell quantity in a unit cryopreservation container is ± 20% of the labeled quantity.
8. The construction method according to claim 6, characterized in that: The qualified standard of the cell phenotype is that the ratio of SOX2 positive cells is not less than 90%; the ratio of NESTIN positive cells is not less than 90%.
9. The construction method according to claim 6, characterized in that: The chromosome karyotype detection comprises the following steps: taking neurospheres cultured to a diameter of 50 μm to 100 μm, inoculating them into a culture bottle coated with matrix gel, and then using G banding to perform chromosome karyotype analysis.
10. The human neural stem cell resource seed bank constructed by the construction method according to any one of claims 1 to 9.
